Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096453 · ClinicalTrials.gov registry record · Phase 1
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
A Phase 1 study of Kidney Transplant; Complications and CMV, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07096453 is a Phase 1 study of Kidney Transplant; Complications and CMV that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 30 participants, below the 120-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07096453, a Phase 1 study of Kidney Transplant; Complications and CMV, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Conditions Studied
Interventions
- DRUG Cytogam
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07096453
The ClinicalTrials.gov registry entry for NCT07096453 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (75% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 1 intervention - of which Cytogam is the first listed.
NCT07096453 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07096453 about?
NCT07096453 is a clinical study titled "CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients". The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
What is the current status of trial NCT07096453?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-02. Estimated completion is 2027-08.
What conditions does trial NCT07096453 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, CMV.
What interventions are being tested in trial NCT07096453?
The interventions under investigation include: Cytogam (DRUG).
Who is sponsoring clinical trial NCT07096453?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096453 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Delayed Tolerance Through Mixed Chimerism
ACTIVE NOT RECRUITING · Phase 1
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
-
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
RECRUITING · NA
-
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
RECRUITING · Phase 2
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.